lifestyle.wordsjournal.com

Author: CALIWAY BIOPHARMACEUTICALS

Caliway’s Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204’s Demonstrated Efficacy and Safety Gain Further Academic Recognition

April 13, 2026
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association’s 2026 Scientific Sessions

April 2, 2026
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026

March 19, 2026
Caliway’s Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies

December 24, 2025
Caliway Biopharmaceuticals Presents Preclinical Research Supporting a Multi-Mechanism Approach to Weight Management at TMASO 2025

December 22, 2025